ADMS:NSD-Adamas Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 4.45

Change

0.00 (0.00)%

Market Cap

USD 0.13B

Volume

0.12M

Average Target Price

USD 7.50 (+68.54%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California. Address: 1900 Powell Street, EmeryVille, CA, United States, 94608

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-29 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD10.72B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

N/A

USD2.97B 29.51 N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.77B 21.77 59.76
APHA Aphria Inc

N/A

USD2.25B 25.85 454.68
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.89B 16.92 14.02
ATNX Athenex, Inc

N/A

USD1.30B N/A N/A
ENDP Endo International plc

N/A

USD1.24B N/A 9.49
TLRY Tilray, Inc

N/A

USD1.23B N/A N/A

ETFs Containing ADMS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.41% 82% B- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.41% 82% B- 67% D+
Trailing 12 Months  
Capital Gain -25.21% 44% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.21% 44% F 16% F
Trailing 5 Years  
Capital Gain -73.05% 29% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.05% 29% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -10.81% N/A N/A 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.81% N/A N/A 17% F
Risk Return Profile  
Volatility (Standard Deviation) 57.70% N/A N/A 19% F
Risk Adjusted Return -18.74% N/A N/A 24% F
Market Capitalization 0.13B 33% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 1.57 31% F 56% F
EV/EBITDA 0.11 100% A+ 96% A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -54.93% 40% F 18% F
Return on Assets -18.69% 40% F 20% F
Debt to Equity Ratio -14,073.24% 100% A+ 100% A+
Technical Ratios  
Short Ratio 6.26 44% F 25% F
Short Percent 4.99% 58% F 38% F
Beta 2.57 9% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector